Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has entered into an agreement to supply certain gold nanorod material to Siva Therapeutics, Inc. ("Siva"), adeveloper of advanced, 'in-vivo' therapies for treating cancer.
Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has entered into an agreement to supply certain gold nanorod material to Siva Therapeutics, Inc. ("Siva"), adeveloper of advanced, 'in-vivo' therapies for treating cancer.
Sona Nanotech announces the termination of its licensing agreement with Arlington Scientific for the Company’s COVID-19 rapid saliva test. The Company will continue to focus its efforts on the development of its concussion and bovine tuberculosis rapid tests, and on the development of its proprietary gold nanorod technology, including manufacturing capabilities, and key research studies to further validate its biocompatibility. The Company is also pleased to announce the dismissal of the class action suit filed in the U.S.
Sona Nanotech Inc. is pleased to announce the appointment of Mr. Neil Fraser and Dr. Walter Strapps, Ph.D., to the Company’s Board of Directors. The company has also arranged a debt settlement of $1,452,724 in amounts owed to Numus Financial Inc., in order to provide the company greater operating flexibility.
Sona Nanotech Inc. is pleased to announce the launch of a new research program to explore the leading attributes of its unique, proprietary gold nanorod technology together with leading experts in the field of bioengineering.
Sona is pleased to announce that it has entered into a binding licensing agreement with U.S. Food and Drug Administration (”FDA”) registered Arlington Scientific Inc. (“ASI” or “Arlington”) of Springville, Utah, an in-vitro diagnostics developer, manufacturer and distributor, to bring Sona’s rapid saliva COVID-19 test to market.
Sona leverages on its core GNR manufacturing technology, scientific experience, and laboratory asset to focus on two strategic priorities for its business: the development of rapid diagnostic tests and biologic reagents, and the advancement of its GNR intellectual property towards important medical in vivo applications.
The study was designed to evaluate the ability to detect the COVID-19 virus in saliva samples using a novel collection device and a rapid antigen test cassette. The Company plans to focus its research strategy on continuing with its other rapid test development programs and research on its proprietary gold nanorod production technology.
As part of the multi-year project, Sona will work closely with other consortium members to leverage bTB biomarker research from Aberystwyth University to develop a rapid, lateral flow assay to identify bTB that differentiates between vaccinated and unvaccinated cows.
As previously announced in the Company’s news release dated April 12, 2021, the trial will occur in partnership with the Humber River Hospital in Toronto, with the objective to determine the clinical performance of the test when compared to RT-PCR, in symptomatic patients.
David Regan, CEO, comments "New, less invasive rapid tests are needed to support frequent testing and a test that works with saliva would make regular testing for everyone much more accessible and tolerable. Developing a rapid antigen test for COVID-19 that works with saliva is complex...
Under the ATM Offering, Common Shares will be distributed at trading prices prevailing at the time of the sale. As such, prices may vary between purchasers and during the period of distribution.
© 2022 Sona Nanotech. All rights reserved. Privacy Policy